On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest company to agree to a new price policy push.

Regeneron Pharmaceuticals Inc. will offer a gene therapy that restored hearing for a small number of profoundly deaf children at no cost after US regulators approved the treatment.

Food and Drug Administration ‌has approved Regeneron's ‌gene therapy for a rare genetic ​form of deafness, the company said on Thursday. The company said the therapy will ‌be available ⁠for free to ...

President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative. US ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.

Regeneron Pharmaceuticals announced that the FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), a bispecific antibody treatment for adult patients with relapsed or refractory ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...